Call Us - We're Easy to Talk To (214) 999-9999

Researchers Find Potentially Dangerous Side Effects Of Arthritis Drug Celebrex

This article was posted today by the University of Buffalo (UB) in its online journal, The Spectrum. The conclusion is that the arthritis drug Celebrex can induce irregular heartbeat rhythms. Here are excerpts:

On average, over one million Celebrex prescriptions are filled each month, according to the Celebrex Web site. Unlike Vioxx, an arthritis medication that was taken off the market in 2004 due to patients reporting cardiovascular side effects, Celebrex has never been pulled off pharmaceutical shelves. Celebrex is a product of Pfizer.

Celebrex works by inhibiting an enzyme called COX-2, which has been shown to induce arrhythmia. According to the American Heart Association Web site, “arrhythmias can occur in a healthy heart and be of minimal consequence.” However, “they also may indicate a serious problem and lead to heart disease, stroke or sudden cardiac death.”

Increased risks of heart attack or stroke are listed as possible side effects of Celebrex and other non-steroidal anti-inflammatory drugs (NSAID) on the Food and Drug Administration’s Web site. Still, Randall D. Shortage, Ph.D., associate professor of biological sciences, said UB’s research finding raises new questions about the drug.

Bob Kraft

I am a Dallas, Texas lawyer who has had the privilege of helping thousands of clients since 1971 in the areas of Personal Injury law and Social Security Disability.

About This Blog

The title of this blog reflects my attitude toward those government agencies and insurance companies that routinely mistreat injured or disabled people. As a Dallas, Texas lawyer, I've spent more than 45 years trying to help those poor folk, and I have been frustrated daily by the actions of the people on the other side of their claims. (Sorry if I offended you...)

If you find this type of information interesting or helpful, please visit my law firm's main website at KraftLaw.com. You will find many more articles and links. Thank you for your time.

Find us on your preferred network